First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with F-T-401
Creators
- Takahata, Keisuke1, 2
- Seki, Chie2
- Sano, Yasunori2
- Yamamoto, Yasuharu2
- Tagai, Kenji2
- Kitamura, Soichiro2
- Matsuoka, Kiwamu2
- Endo, Hironobu2
- Shinotoh, Hitoshi2
- Takado, Yuhei2
- Higuchi, Makoto2
- Kimura, Yasuyuki3, 2
- Ichise, Masanori3, 2
- Kubota, Manabu4, 2
- Shimada, Hitoshi5, 2
- Kawamura, Kazunori6
- Zhang, Ming-Rong6
- 1. Department of Neuro-Psychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo (Japan)
- 2. Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, 263-8555, Chiba, Chiba (Japan)
- 3. Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, 7-430 Morioka, Obu, Aichi (Japan)
- 4. Department of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto (Japan)
- 5. Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, 1-757 Asahimachi-Dori, Chuo, Niigata, Niigata (Japan)
- 6. Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage, Chiba, Chiba (Japan)
Description
Monoacylglycerol lipase (MAGL) regulates cannabinoid neurotransmission and the pro-inflammatory arachidonic acid pathway by degrading endocannabinoids. MAGL inhibitors may accordingly act as cannabinoid-potentiating and anti-inflammatory agents. Although MAGL dysfunction has been implicated in neuropsychiatric disorders, it has never been visualized in vivo in human brain. The primary objective of the current study was to visualize MAGL in the human brain using the novel PET ligand F-T-401. Seven healthy males underwent 120-min dynamic F-T-401-PET scans with arterial blood sampling. Six subjects also underwent a second PET scan with F-T-401 within 2 weeks of the first scan. For quantification of MAGL in the human brain, kinetic analyses using one- and two-tissue compartment models (1TCM and 2TCM, respectively), along with multilinear analysis (MA1) and Logan graphical analysis, were performed. Time-stability and test-retest reproducibility of F-T-401-PET were also evaluated. F-T-401 showed rapid uptake and gradual washout from the brain. Logan graphical analysis showed linearity in all subjects, indicating reversible radioligand kinetics. Using a metabolite-corrected arterial input function, MA1 estimated regional total distribution volume (V) values by best identifiability. V values were highest in the cerebral cortex, moderate in the thalamus and putamen, and lowest in white matter and the brainstem, which was in agreement with regional MAGL expression in the human brain. Time-stability analysis showed that MA1 estimated V values with a minimal bias even using truncated 60-min scan data. Test-retest reliability was also excellent with the use of MA1. Here, we provide the first demonstration of in vivo visualization of MAGL in the human brain. F-T-401 showed excellent test-retest reliability, reversible kinetics, and stable estimation of V values consistent with known regional MAGL expressions. PET with F-T-401-PET is promising tool for measurement of central MAGL.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-021-05671-yAdditional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 49
- Journal Issue
- 9
- Journal Page Range
- p. 3150-3161
- ISSN
- 1619-7070
- CODEN
- EJNMA6
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 53092746
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ARACHIDONIC ACID; ARTERIES; BEHAVIOR; BLOOD FLOW; CEREBRAL CORTEX; FLUORINE 18; IN VIVO; INFLAMMATION; LIGANDS; LIPASES; METABOLITES; NERVOUS SYSTEM DISEASES; POSITRON COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RELIABILITY; SAMPLING; THALAMUS; UPTAKE
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BLOOD VESSELS; BODY; BRAIN; CARBOXYLESTERASES; CARBOXYLIC ACIDS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CEREBRUM; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; ENZYMES; ESTERASES; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; HYDROLASES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MATERIALS; MONOCARBOXYLIC ACIDS; NANOSECONDS LIVING RADIOISOTOPES; NERVOUS SYSTEM; NUCLEI; ODD-ODD NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; PROTEINS; RADIOACTIVE MATERIALS; RADIOISOTOPES; SYMPTOMS; TOMOGRAPHY
Optional Information
- Notes
- Advanced Image Analyses (Radiomics and Artificial Intelligence)